This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Key innovation: Leading companies in nanoparticles for drugdelivery. Bristol-Myers Squibb is the leading patent filer in nanoparticles for drugdelivery.
On May 5, a panel of experienced industry experts will discuss recent developments during Innovations in DrugDelivery, a free one-hour industry webinar.
Akouos focuses on developing adeno-associated viral gene therapies to treat inner ear conditions, including sensorineural hearing loss. It has combined expertise in otology, gene therapy and inner ear drugdelivery to meet the requirements of individuals with disabling hearing loss globally.
In 1974, Dr. Robert Langer was part of the first cohort of researchers to begin nanoparticle research , as his lab at Cornell University developed tiny particles to deliver large molecules for angiogenesis. Since then, the drug has been used off-label in breast cancer and other types of cancer.
Paris, will open in May (18-19) with connectivity, sustainability and user experience identified as the key trends in 2022 influencing innovation across pharmaceutical packaging and drugdelivery. Pharmapack Europe will be held as Smart Event to enhance the benefits for global attendees, providing a hybrid experience that extends the.
Maculus plans to raise USD3 million on a USD8 million valuation for a 12-18 month period, including initial in-vivo animal studies and completion of in-vitro / in-vivo drug elution studies. Maculus achieved the breakthrough using a patented novel tunable biodegradable proprietary product, MacuBloc. Capable of delivering any FDA approved.
Highlights include expansion of biotech operations in Philadelphia, acquisition of a new pharma-device facility near Dublin, Ireland, and a new Center of Excellence for advanced drugdelivery and drug-device combination product assembly in Rockford, Illinois.
Lenz, Principal Medical Device Regulation Expert — For several years, FDA has requested that sponsors of drug or biologic led combination products identify essential performance requirements (EPRs) related to the device constituent in their applications. By Adrienne R. does not use this term.
Interest in the pulmonary route has also grown in recent years because delivering the drugs through the lungs allows direct systemic delivery and bypasses the first pass metabolism. Why is pulmonary drugdelivery a complex challenge? How can we accomplish drugdelivery to the lungs in nonclinical studies?
Clinical-stage drugdelivery and development company DelSiTech has made the biggest single financing round in its history with the successful completion of a â10 million deal.
at Northwestern University—has developed novel technology with the potential to change the future of drugdelivery. A team of scientists—led by Yamin Zhang, Ph.D., and Colin Franz, MD, Ph.D., at Shirley Ryan AbilityLab and John Rogers, Ph.D.,
A team of scientists from the universities of Glasgow and Tel Aviv has developed a groundbreaking method to transform the brain parasite Toxoplasma gondii into a potential vehicle for delivering therapeutic treatments directly to brain cells.
Genentech’s ocular implant drugdelivery system for treatment of macular degeneration has received approval from the US Food and Drug Administration (FDA). Susvimo delivers ranibizumab via a port delivery system into a surgically placed implant in the eye, allowing for continuous delivery of the drug.
Lipid nanoparticle systems (LNPs) as a delivery mechanism for novel drug modalities are proving effective, but there are bioanalytical challenges associated with encapsulation, says an expert.
Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. The FDA has also recently launched the Software Pre-Certification Pilot Program to provide an efficient regulatory framework for developers of SaMD products.
DrugDelivery Devices Symposium. We have the distinct privilege of unveiling Oxford Global’s DrugDelivery Devices Symposium, taking place on the 10th of March, 2021. Discuss Combination Product Development & Engineering with leading experts such as Andrew Yum , United Therapeutics and Ning Yu , Biogen.
US-based development-stage biopharmaceutical firm Satsuma Pharmaceuticals is developing STS101, a unique nasal powder formulation of the anti-migraine drug dihydroergotamine mesylate, for the treatment of acute migraine. We believe that STS101 will contribute to improving the quality of life of patients suffering from migraine.
SMi presents the 4 th Annual Ophthalmic Drugs Conference taking place on the 23 rd -24 th November 2020, in London. Workshop will be on ‘Ophthalmic DrugDeliveryDevelopment – Trials and Tribulations’. Understanding the pharmacological challenges for DD and development pathway including cost and timelines.
Novartis has formed a strategic collaboration with drugdelivery specialist Lindy Biosciences to develop self-administered versions of the Swiss pharma’s innovative drugs.
Ceapro has extended a partnership underway to carry out a further research project with McMaster University for developing an inhalable immuno-therapeutic/-prophylactic for Covid-19-induced lung fibrosis. This project is intended to develop therapies for people suffering from Covid-19’s long-term effects.
Fear of needles, injection-associated infection and pain are responsible for patients skipping doses, which encourages the development of new delivery strategies that combine efficacy with limited side effects to treat patients adequately.
Sixfold Bioscience in partnership with Medicines Discovery Catapult, has been given the green light, through the award of an Innovate UK Smart Grant to test a pioneering system designed to deliver drugs directly to cancerous cells, without impacting the healthy cells around it.
Samyang has entered into a strategic partnership agreement with LG Chem to develop new cancer therapeutics using Samyang’s technology, NanoReady. LG Chem will use the technology for the development of innovative mRNA-based cancer therapeutics with maximised therapeutic efficacy.
Over the last two decades, the pharmaceutical industry has observed a paradigm shift from conventional drugdelivery strategies to the long-acting drugdelivery (LADD) of products to treat several disease indications, such as ophthalmic disorders, oncological disorders, neurological disorders and infectious diseases.
The purpose of writing this review on floating drugdelivery systems (FDDS) was to The recent developments of FDDS including the physiological and formulation variables affecting gastric retention, approaches to design single-unit and multiple-unit floating systems, and their classification and formulation aspects are covered in detail.
has unveiled its Alternative Methods Advancement Project (AMAP), a strong initiative aimed at changing drug discovery and development by exploring alternatives to animal testing. Charles River Laboratories International, Inc.
Interestingly, over the past few years, drugdevelopers focused on non-respiratory diseases have also shifted their attention towards intranasal drug formulations. This can be attributed to ease of delivery, increased bioavailability and by-pass of first-pass metabolism offered by this type of route of administration.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health, has awarded a total of $577m to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.
After proving the merits of its drugdelivery platform last year with the approval of Teva’s long-acting schizophrenia drug Uzedy, France’s Medincell has hooked another big-name partner. Medincell and AbbVie inked a development and licensing pact to create up to six long-acting injectables, Medincell said Wednesday.
Sorrento Technologies, a biotech firm developing novel treatments for COVID-19 and aggressive cancers such as melanoma, has received FDA clearance to start a research collaboration together with Mayo Clinic.
Ophthalmic technology firm Eyenovia and Formosa Pharmaceuticals have entered a collaboration agreement to develop new ophthalmic therapeutics. The collaboration will combine the Optejet dispensing technology of Eyenovia with the APNT nanoparticle formulation platform of Formosa to develop topical therapeutics.
Global Biotechnology, DrugDevelopment and DrugDelivery Systems Nanoparticles Markets, 2019-2020 & 2025 – ResearchAndMarkets.com Global Biotechnology, DrugDevelopment and DrugDelivery Systems Nanoparticles Markets, 2019-2020 & 2025 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Nanoparticles in Biotechnology, (..)
Texas A&M associate professor Akhilesh Gaharwar and graduate student Patrick Lee are developing a new class of hydrogels that can leverage light for drugdelivery and regenerative medicine treatments. However, once inside, they can be challenging […].
Therefore, medical technology is rapidly evolving, enabling more advanced and patient-friendly methods of drugdelivery. In the pursuit of creating patient-centric healthcare solutions, the medical industry has witnessed a groundbreaking advancement in drugdelivery with the emergence of large volume wearable injectors.
The repurposing of FDA-approved drugs for alternative diseases is a faster way of bringing new treatments into the clinic. Researchers at Karolinska Institutet in Sweden have repurposed a cancer drug for treatment of neuroinflammatory diseases such as multiple sclerosis.
Celsion GmbH Announces the Publication of an Article Reviewing the History of ThermoDox® DrugDevelopment in Advanced DrugDelivery Reviews Celsion GmbH Announces the Publication of an Article Reviewing the History of ThermoDox® DrugDevelopment in Advanced DrugDelivery Reviews … Continue reading →
CPhI Worldwide will see Gerresheimer showcase its latest developments in primary packaging, drugdelivery systems for newly developed biologics along with medical and diagnostic products.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content